Tanvimil Folico

Quick links

Choose a section

Quick links to important sections

Advertisements

Tanvimil Folico

Advertisements

Overview of Tanvimil Folico

What is Tanvimil Folico?

Tanvimil Folico is a vitamin supplement primarily composed of folic acid, also known as vitamin B9. Folic acid is a water-soluble B-complex vitamin that is essential for several fundamental biological processes within the human body.

Role and Function

The active component in Tanvimil Folico plays a critical role in the synthesis of nucleic acids, which are the building blocks of DNA and RNA. By assisting in genetic material production, it facilitates proper cell division and growth. This makes it particularly significant in tissues that undergo rapid turnover, such as the blood and skin.

Hematological Support

Folic acid is necessary for the maturation of red blood cells in the bone marrow. It works alongside other B vitamins to ensure that red blood cells are formed correctly and in sufficient quantities to transport oxygen throughout the body.

Nutritional Context

While folic acid is found naturally in various foods—including leafy green vegetables, legumes, and citrus fruits—Tanvimil Folico provides a concentrated form of the vitamin. It is used to address nutritional requirements or to manage physiological states where the demand for vitamin B9 increases, helping to maintain necessary systemic levels when dietary intake alone may not be sufficient.

Advertisements

What side effects are possible with Tanvimil Folico?

Possible side effects and safety information

Regulatory documents classify the adverse reactions associated with Folic Acid, the active ingredient in Tanvimil Folico, primarily by physiological system and frequency.

Adverse Reactions and Systemic Groupings

Adverse effects are generally infrequent at standard therapeutic doses. According to official regulatory standards, reactions such as certain Gastrointestinal Disorders (e.g., abdominal distension, nausea, or anorexia) and Immune System Disorders (e.g., skin rash, pruritus, or urticaria) are classified as Rare events.

System-Organ Class Rare Manifestations (Official Classification)
Immune System Disorders Allergic reactions (rash, pruritus, erythema, urticaria)
Gastrointestinal Disorders Anorexia, nausea, abdominal distension, flatulence

Serious Safety Constraints

The most critical safety constraint documented in official labeling relates to the potential for Folic Acid to mask the symptoms of an underlying Vitamin B12 deficiency (Cobalamin deficiency). Treating megaloblastic anemia with Folic Acid alone may allow the hematological signs to improve while simultaneously permitting irreversible neurological damage, such as subacute combined degeneration of the spinal cord, to progress. For this reason, the administration of Folic Acid is restricted in patients with undiagnosed megaloblastic anemia.

Isolated, severe Immune System Disorders, including Anaphylactic Reaction/Shock, have also been documented in post-marketing reports.

Exposure-Dependent Patterns

Specific effects on the Nervous System (such as sleep disturbances, irritability, or difficulty concentrating) are officially documented, but are associated only with the chronic administration of very high doses of Folic Acid, not with standard supplementation.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

Folic acid is generally considered to have a very low risk of acute toxicity, as the body can effectively clear excess amounts. When high doses are administered, the surplus folic acid is rapidly eliminated through the urine. Due to this efficient renal clearance, regulatory documents indicate that intoxication is not possible at usual therapeutic doses.

However, a principal concern associated with high and continuous intake of folic acid is its ability to mask the hematological symptoms of a Vitamin B12 deficiency (pernicious anemia). High doses can improve blood counts while failing to correct the underlying and potentially irreversible neurological damage that can occur when Vitamin B12 deficiency goes untreated. This masking effect is considered the most serious adverse outcome of excessive folic acid use.

While there have been no reported cases of acute overdose necessitating treatment, official regulatory guidance requires specific action in the event that an overdose is suspected. If there is a possibility of taking too much of the product, individuals are explicitly instructed to go to the nearest hospital or contact a poison control or toxicology center for immediate medical evaluation.

In rare circumstances, very high doses have been associated with symptoms such as gastrointestinal disturbances, irritability, or sleep issues. Regardless of the symptoms, any suspected overexposure requires urgent medical attention to rule out complications, especially those related to potential masking of an underlying Vitamin B12 deficiency.

Advertisements

Therapeutic Uses of Tanvimil Folico

What Tanvimil Folico treats: main uses and benefits

Tanvimil Folico is commonly used to help with two main therapeutic areas: managing the symptoms of folate deficiency-related anemia and providing key support for prenatal development.

This medication is applied across conditions involving episodic or fluctuating manifestations of a vitamin shortage, typically due to dietary inadequacies or malabsorption issues. Symptomatically, it helps address manifestations such as pervasive fatigue and general weakness. For individuals planning or in the early stages of pregnancy, its use may assist in reducing the likelihood of certain serious birth defects affecting the baby's brain and spinal cord. In these scenarios, the medication provides support that helps ease the overall symptom burden and supports general well-being during symptomatic periods.

“This treatment is relevant for easing symptoms that interfere with daily comfort and may assist with maintaining functional stability.”


Quick Fact: Relief for Fatigue and Weakness
Tanvimil Folico is commonly used to help with managing the significant tiredness and lack of vitality associated with anemia caused by low folate levels.
Advertisements

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Tanvimil Folico

Eligibility Scope Official Regulatory Status
Absolute Contraindications Prohibited for patients with a known hypersensitivity to the drug or any of its excipients. Contraindicated in cases of untreated pernicious anaemia or undiagnosed Vitamin B12 deficiency to prevent neurological damage progression.
Conditional Restrictions Use in malignant disease (cancer) is restricted unless the megaloblastic anaemia is definitively confirmed to be due to folate deficiency. Long-term therapy in older adults may require initial screening for Vitamin B12 deficiency.
Standard Eligibility Use is permitted for most adults and children. Pregnant and breastfeeding women are explicitly recognized as eligible populations for prophylactic and treatment purposes.
Physiological/Age Groups Infants and Children are permitted for use. Women of childbearing age are recommended users. Use is documented as acceptable during pregnancy and lactation.

Eligibility Classifications

Official regulatory documents define eligibility for this medicine primarily by excluding patients with two critical pre-existing conditions: known hypersensitivity and untreated Vitamin B12 deficiency. The major regulatory constraint is the risk associated with Vitamin B12 deficiency, where Folic Acid is strictly prohibited as a single agent because it can mask the hematological symptoms while allowing irreversible neurological damage to advance. Use is generally permitted across age groups and is explicitly allowed during pregnancy and breastfeeding, consistent with its classification as an essential nutrient.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information identifies specific substances and conditions that interact with Folic Acid (the active ingredient in Tanvimil Folico).

Contraindicated Combination

Folic Acid is contraindicated for administration as a single agent in the treatment of undiagnosed megaloblastic anemias where Vitamin B12 deficiency exists. This restriction is enforced because Folic Acid may obscure the diagnosis by resolving hematologic symptoms while allowing progressive and irreversible neurological damage to advance.

Drug-Drug Interactions

The most clinically significant interactions involve certain Anticonvulsants, such as phenytoin, phenobarbital, and primidone. Folic Acid has been reported to decrease the serum levels of these agents, which may antagonize their anticonvulsant action. Additionally, co-administration with Folic Acid Antagonists (e.g., methotrexate, trimethoprim) may result in the mutual inhibition of the respective effects of both medicinal products (pharmacodynamic opposition).

Absorption and Timing Constraints

Several substances reduce the absorption of Folic Acid, requiring mandatory time separation. Antacids (containing aluminum or magnesium) should be administered at least two hours after Folic Acid. Likewise, Cholestyramine requires a significant separation window, with Folic Acid taken 1 hour before or 4 to 6 hours after the sequestrant. Other agents like Sulfasalazine also reduce Folic Acid absorption.

Other Substances and Condition Notes

Interactions are documented with certain cytostatic agents, where high doses of Folic Acid may increase drug-related toxicity (e.g., severe diarrhea with Fluorouracil). The label also notes that alcohol consumption contributes to increased folate elimination, and Folic Acid may reduce the intestinal absorption of the supplement Zinc.

Advertisements

Mechanism of Action

Tanvimil Folico, a source of folic acid (Vitamin B9), functions by providing a metabolic precursor essential for one-carbon metabolism. The compound is converted to tetrahydrofolate (THF), a key coenzyme for two distinct mechanistic domains that govern cellular processes.

Cofactor Engagement in Nucleotide Synthesis

THF acts within pathways for de novo synthesis of purine and pyrimidine bases (thymidylate). This molecular role is crucial for DNA and RNA synthesis and repair, directly contributing to the formation and maturation of cells, particularly those that require rapid division.

Regulation of Amino Acid Metabolism

The active form of folate, 5-methyl-THF, engages mechanisms that facilitate the enzymatic conversion of the amino acid metabolite homocysteine into methionine via methionine synthase. This cascade influences the flux of methyl groups, thereby modulating metabolic pathways associated with amino acid balance and cellular signaling.

Advertisements

Dosage and Administration Information

How to Use Tanvimil Folico

Tanvimil Folico, which contains Folic Acid, is administered according to specific regimens for therapeutic and prophylactic purposes. The standard method of administration is the Oral Route, typically using a tablet or capsule. Although oral use is the primary method, the parenteral route (intramuscular, intravenous, or subcutaneous injection) is available for use in particular clinical circumstances.


Official Dosing and Administration Parameters

Dosing is strictly differentiated based on the treatment objective and patient demographic:

  • Therapeutic Regimen for Deficiency: For adults with established folate deficiency, the usual daily dose may be up to 1 mg daily, though certain protocols specify a dose of 5 mg daily. This higher dose is typically maintained for a course of four months or until the blood parameters normalize.

  • Prophylactic and Maintenance Use: For long-term prevention or maintenance after correction of a deficiency, adults generally transition to a lower dose, often 0.4 mg (400 micrograms) to 1 mg daily.

  • Dosing in Pregnancy (High-Risk): For the prevention of neural tube defects in high-risk scenarios, a regimen may involve 5 mg daily, commencing prior to conception and continuing through the first trimester.


Procedural Constraint on Administration

The frequency of administration is generally once daily for both therapeutic and maintenance regimens. A critical procedural constraint is that Folic Acid doses exceeding 0.1 mg daily must not be administered in cases of undiagnosed megaloblastic anemia unless co-existing Vitamin B12 deficiency is concurrently being treated or has been definitively excluded. This ensures adherence to standardized use protocols.

Advertisements

Recent Clinical Evidence

Research Overview

Clinical evidence regarding folic acid (Vitamin B9) focuses primarily on its established role in fetal development and cell division. Tanvimil Folico contains the synthetic form of this B vitamin, which is utilized by the body to support processes like DNA synthesis and repair. The body of research is extensive, encompassing large-scale randomized controlled trials (RCTs) and systematic reviews.


Primary Clinical Findings

Research Focus Key Reported Outcome Relevant Study Types
Neural Tube Defects (NTDs) Periconceptional supplementation is associated with a reduction in the risk of NTDs, such as spina bifida and anencephaly. RCTs, Meta-analyses, Observational studies
Maternal Folate Status Supplementation is effective in increasing red blood cell (RBC) folate concentrations, a biomarker for folate status, particularly when initiated before conception. Cohort studies, RCTs

Key Research Details

Evidence confirms that adequate maternal folate intake in the periconceptional period (the time just before and after conception) is a significant factor in preventing NTDs. Observational and randomized trials have established that daily folic acid supplementation is linked to a substantially lower occurrence of these defects in infants. The timing of intake is critical, as the neural tube forms early in embryonic development (typically within the first month of pregnancy).

Additional Research Context: Some studies have explored the impact of folic acid on other outcomes, including cardiovascular markers like homocysteine levels and potential protective roles against certain environmental chemical exposures during pregnancy. However, the evidence for these secondary applications remains less conclusive or is still under investigation compared to the established role in NTD prevention.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Tanvimil Folico (FAQ)


Q: Is Tanvimil Folico the same as generic folic acid?

A: The active component of Tanvimil Folico is Folic Acid, which is described in regulatory documents as the same essential chemical substance found in generic products. Official regulatory standards ensure that the purity and potency of this active ingredient are consistent across all products. However, these standards generally do not address potential differences in the inactive ingredients (excipients) used in branded versus generic versions.


Q: Is there a maximum age limit for using Tanvimil Folico?

A: Official regulatory guidelines do not specify a maximum age limit for using this product; use is generally permitted across all adult age groups, consistent with its classification as an essential nutrient. Official documentation does note that patients receiving long-term therapy, particularly older adults, may need initial screening to help rule out an underlying Vitamin B12 deficiency.


Q: Are the research findings on Tanvimil Folico considered reliable?

A: Studies on Folic Acid, the component in Tanvimil Folico, are extensively reviewed by expert health groups and government bodies worldwide. These reviews confirm that the product's established uses are based on consistent scientific evidence. For instance, its use in preventing specific birth defects is often supported by the highest level of recommendation from major preventive health task forces.


Q: What is the difference between folate and folic acid?

A: Folate is the naturally occurring form of Vitamin B9 found in foods. Folic acid, which is the component in Tanvimil Folico, is the stable, synthetic (man-made) form of this vitamin. Folic acid is the specific form that is supported by clinical studies and regulatory reviews for its role in helping to reduce the risk of certain birth defects in the periconceptional period.


Q: Is it possible to take too much of the ingredients found in Tanvimil Folico?

A: Yes. Official product information notes that certain Nervous System effects are documented in association with the chronic administration of very high doses, including sleep disturbances, irritability, or difficulty concentrating. Other physical effects, such as a bitter taste or loose stools, have also been noted with high intake.


Q: What is the typical timeframe for benefits described in studies of Tanvimil Folico?

A: The timeframe varies depending on the purpose of use. For the key prophylactic use of preventing neural tube defects, official guidance specifies that adequate intake should be established at least one month before conception. For the therapeutic treatment of an established deficiency, a full course of about four months or until blood parameters normalize is typically cited in clinical regimens.


Q: Is Tanvimil Folico regulated by the FDA or a similar government body?

A: Yes. The active ingredient, Folic Acid, and all pharmaceutical products containing it are subject to strict regulation by governmental health authorities in various jurisdictions, such as the FDA (US), EMA (EU), and TGA (Australia). These authorities define the standards for its manufacturing, labeling, purity, and authorized uses.


Q: Do men ever need to take Tanvimil Folico?

A: Yes. Official dosing recommendations for the treatment of an established folate deficiency and for general maintenance purposes apply to all adults, regardless of gender. The product’s core function is to support cell division and maturation, which is an essential metabolic process for everyone.


Q: Is Tanvimil Folico available without a prescription?

A: In many countries, the availability of Tanvimil Folico depends on the strength of the tablet. Lower-dose tablets (such as 400 micrograms) are widely available without a prescription from pharmacies and supermarkets. However, higher therapeutic doses, which are used to treat specific deficiencies, often require a prescription.


Q: Does Tanvimil Folico interact with birth control pills?

A: Regulatory reviews have noted that women using oral contraceptives may have slightly lower serum levels of folate and Vitamin B12. Due to this potential effect, clinicians sometimes advise women to ensure they have adequate folate stores before trying to conceive after stopping the contraceptive pill.


Q: Can I take Tanvimil Folico with common over-the-counter pain relievers?

A: Official drug interaction summaries generally indicate that Folic Acid can typically be taken at the same time as common everyday painkillers such as paracetamol (acetaminophen). Caution is noted regarding combinations with NSAIDs (like ibuprofen) only in specific clinical scenarios, such as when a patient is also receiving treatment with methotrexate.


Q: What happens if I forget to take Tanvimil Folico one day?

A: The standard general guidance found in patient information for once-daily medication is to take the forgotten dose as soon as it is remembered on the same day. If the missed dose is not remembered until the next day, patient information leaflets often advise skipping the missed dose to avoid taking a double amount.


Q: Does taking Tanvimil Folico affect blood test results?

A: Taking Folic Acid at recommended amounts is not known to delay the detection of an underlying Vitamin B12 deficiency when modern laboratory tests are used to directly measure B12 status. The primary purpose of the product in deficiency is to normalize specific blood parameters related to red blood cell health.


Q: What is the general safety classification of Tanvimil Folico?

A: Folic Acid tablets are classified as non-hazardous according to international standards for workplace safety, reflecting a low immediate hazard profile for handling. In terms of EU safety standards, the product is officially listed as "Not classified" for general indication of danger.


Q: Can people with kidney problems use Tanvimil Folico?

A: Yes, use is conditionally permitted. The official FDA label includes specific dosing guidance for patients undergoing hemodialysis, which is a common treatment for severe kidney disease. This indicates that the use of Tanvimil Folico is allowed in these patients, often with dose adjustment or specific monitoring.


Q: Do people with certain digestive issues absorb Tanvimil Folico differently?

A: Yes, this is officially noted in medical literature. Conditions such as celiac disease and inflammatory bowel disease (IBD) are known to cause impairment in the small intestine’s ability to absorb nutrients. This can result in low folate levels, which may necessitate specific supplementation strategies.


Q: Is it true that Tanvimil Folico can help with energy levels?

A: Folate deficiency can lead to a type of anemia where one of the common symptoms is feeling tired or experiencing heart palpitations. By supporting the healthy formation of red blood cells, which transport oxygen through the body, the product addresses the fatigue that is specifically associated with this nutritional deficiency.


Q: What happens if I stop taking Tanvimil Folico suddenly?

A: Suddenly stopping the medication may cause the condition being treated to worsen or potentially result in unwanted side effects as the body's levels return to pre-treatment status. Patient information suggests that if the product is intended for long-term use, the cessation process may involve a gradual reduction in the amount.


Q: Are there any specific warnings about driving or operating machinery while using Tanvimil Folico?

A: Official patient information states that the medicine is not expected to affect the ability to drive a car or operate machinery. However, this advice is typically followed by a general caution to observe how the medicine affects an individual before engaging in activities that require focus and attention.


Advertisements

How should Tanvimil Folico be stored and disposed of?

How to Store and Dispose of Tanvimil Folico

Official Storage Requirements

Storage conditions are defined by official labeling to ensure the medicine remains stable and effective:

  • Tanvimil Fólico 1 mg and 5 mg tablets must be conserved within a specific temperature range, between 15 C and 30 C.
  • Tanvimil Fólico 10 mg tablets must be conserved in a cool, dry place and protected from light.

Child-Safety and Handling

All strengths of the medication must be stored out of the reach of children, as required by regulatory labeling.

Disposal Instructions

Official regulatory documents reviewed do not explicitly specify detailed household or pharmaceutical waste handling instructions for the disposal of unused or expired product.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Tanvimil Folico found in:

A-Z Index: